Borregaard Q2 2026 slides: resilient EBITDA amid cost pressures

Borregaard reported Q2 2026 EBITDA of NOK 515m (-1% YoY) and operating revenues up 3% to NOK 2,114m, but posted EPS of NOK -1.27 due to NOK 367m in one-time charges (plus NOK 337m impairment of Alginor). Cash generation was a bright spot with operating cash flow of NOK 695m (vs NOK 385m a year ago) driven by a NOK 325m working-capital release, while leverage stayed low at 1.20x net debt/EBITDA (below a 3.50x covenant). Guidance updates were mixed: BioSolutions volume forecast cut to ~335k tonnes (from 340k), while BioMaterials was raised to >160k tonnes and Fine Chemicals signaled improving volume/mix with caution on H2 bioethanol deliveries.

Analysis

The key mechanism here is not headline earnings quality but the gap between cash generation and reported EPS: that usually supports a tighter credit spread before it supports a higher equity multiple. BRGAY looks like a self-help story with low leverage and credible near-term cash conversion, but the market should be careful about capitalizing 2026 strength as if it were all structural — a meaningful slice is FX, working-capital release, and mix. The immediate winner is the equity itself on any pullback-to-quality trade; the bigger loser may be higher-cost niche specialty chemical peers that cannot absorb the same energy/currency volatility without margin erosion.

Second-order, the operating update is more relevant for competitors in cellulose ethers/specialty cellulose than for the broader materials complex: Borregaard’s willingness to push selective price increases suggests the market may be less forgiving to undifferentiated bio-based inputs. That creates pressure on smaller European niche producers and on Chinese exports if end-markets remain price-sensitive. The debottlenecking project is the real medium-term catalyst, but it is a 2027 story, so the equity can stall if investors realize the current quarter is doing more work than the next two.

The contrarian miss is timing: the cost-savings program does not fully land until 2028, while FX and energy can reverse in weeks, not years. If USD/NOK and EUR/NOK move back against the company or if energy spikes again, EBITDA could retrace even with stable volumes. Conversely, if the CMD in September gives hard numbers on debottlenecking and savings realization, the stock can re-rate as a compounder rather than a cyclical quality name.

Key Decisions for Investors

• Do not chase the post-result move; wait for a 5-8% pullback in BRGAY or a better entry after the September 17 CMD for a medium-term long.
• If already long BRGAY, keep it but trail stops on any sign that 3Q volume or pricing underwhelms; thesis breaks if FX basket strength reverses and FY26 EBITDA guidance is cut.
• Relative-value idea: long BRGAY vs short a higher-cost European specialty chemicals basket (e.g., XLB/sector proxy) if you want exposure to pricing discipline and balance-sheet resilience rather than beta.
• Watch for confirmation that 2027 debottlenecking lifts specialty-cellulose output without margin dilution; if capex rises without a clear payback, fade the rerating.
• No aggressive short here: low leverage and strong operating cash flow make downside more about multiple compression than balance-sheet stress, so a short needs a macro/FX catalyst.